Hester Biosciences rose 1.09% to Rs 1815 after Hester Biosciences Nepal developed and launched its Live Thermo-tolerant PPR vaccine - Nigerian 75/1 Strain.
Hester Nepal recently got the regulatory approval and marketing authorisation from Department of Drug Administration (DDA), Nepal, for its commercial production and marketing. The vaccine has also been tested for thermo-stability and has received a quality certification from The Pan African Veterinary Centre of the African Union (AU-PANVAC).
"Hester is now geared up for commercial production and marketing of its thermo-tolerant PPR vaccine from December 2020. The vaccine will be available in packs of 25, 50 and 100 doses, the company said in a BSE filing made during market hours today.
PPR (Peste Des Petits) or small ruminant plague is a disease of sheep and goat, with a significant impact on the livelihoods and food security of small livestock keepers across the globe, wherein 1.44 billion small ruminants are at risk and on an average 30 million animals are affected annually.
As most of the small ruminant keepers are in rural areas, the thermo-tolerant characteristic of this vaccine will ensure safe delivery of a stable vaccine in remote areas of the world where cold chain maintenance is a challenge. The thermo-tolerant vaccine could overcome the last-mile-delivery challenges.
Hester India as well as Hester Nepal have already been manufacturing the standard (non thermo-tolerant) PPR vaccine since over 5 years. The thermo-tolerant PPR vaccine will add to its range for a specific rural and backyard market mainly covering small holder livestock keepers, worldwide.
Hester Biosciences is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include poultry division and large animal division.
On a consolidated basis, the company's net profit rose 2.5% to Rs 6.68 crore on a 20.8% jump in net sales to Rs 53.41 crore in Q2 FY21 over Q2 FY20.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
